The efficacy of pyriproxyfen against the Australian salt-marsh mosquito, Aedes vigilax, was examined in 2 laboratory and 1 semi-field study using both technical grade and formulated products. In a dose–response study, the median emergence inhibition (EI50) and EI95 values were determined to be 0.019 and 0.076 ppb, respectively, for pyriproxyfen technical grade, 0.021 and 0.092 ppb for a microencapsulated formulation (Sumilarv® 90CS), and 0.054 and 0.236 ppb for the formulated s-methoprene product, Altosid™ Liquid Larvicide. A further laboratory comparison of the microencapsulated formulation of pyriproxyfen and Altosid, at the nominal field rate for Altosid, showed that both products provided 100% emergence inhibition and this was confirmed in a semi-field study, which also included a granular formulation of pyriproxyfen (Sumilarv 0.5G).
How to translate text using browser tools
1 March 2012
Pyriproxyfen for the Control of Australian Salt-Marsh Mosquito, Aedes vigilax
Garry Webb,
Peter Miller,
Bryce Peters
ACCESS THE FULL ARTICLE
It is not available for individual sale.
This article is only available to subscribers.
It is not available for individual sale.
It is not available for individual sale.
Aedes vigilax
Altosid™
insect growth regulators
pyriproxyfen
s-methoprene
Sumilarv®